Apricus Biosciences, Inc.
22.05.2013 22:01
---------------------------------------------------------------------------
SAN DIEGO, 2013-05-22 22:01 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI) today
announced that it intends to offer shares of common stock and warrants in an
underwritten public offering. The Company also expects to grant the
underwriters a 30-day option to purchase additional shares of common stock and
warrants to cover over-allotments, if any. Lazard Capital Markets LLC is acting
as sole book-running manager for the offering. While the offering is expected
to price before 9:30 am EDT on May 23, 2013, the offering is subject to market
conditions, and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the offering.
A registration statement relating to the common stock and warrants issued in
the offering has been filed with, and declared effective by Securities and
Exchange Commission (the 'SEC'). A preliminary prospectus supplement, as well
as a final prospectus supplement, relating to the offering will be filed with
the SEC, each of which will form a part of the effective registration
statement. When available, copies of the preliminary and final prospectus
supplements and the accompanying base prospectus relating to these securities
may be obtained by visiting the SEC's website at www.sec.gov or Lazard Capital
Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via
telephone at (800) 542-0970.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities
laws of any such jurisdiction.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros(r), for the treatment of
erectile dysfunction, which will be marketed in Canada by Abbott Laboratories,
and Femprox(r), a product candidate, for the treatment of female sexual arousal
disorder.
Forward-Looking Statements
This press release contains forward-looking statements, including statements
related to Apricus Biosciences, Inc.'s public offering of common stock and
warrants and the completion, timing and size of the offering that involve risks
and uncertainties. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,'
'intend,' 'will,' 'goal,' 'potential' and similar expressions are intended to
identify forward-looking statements. These forward-looking statements are based
upon Apricus Biosciences, Inc.'s current expectations. Actual results and the
timing of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and uncertainties, which
include, without limitation, risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions related to the
proposed offering and other risks detailed in Apricus Biosciences, Inc.'s
filings with the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement, and Apricus Biosciences, Inc.
undertakes no obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date of this press release.
CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
News Source: NASDAQ OMX
22.05.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences Announces Proposed Public Offering of Common Stock and Warrants
| Source: EQS Group AG